Streetbeat News

Analyst Ratings

AMAT

Cantor Fitzgerald analyst C J Muse has reiterated an Overweight rating on Applied Materials (NASDAQ:AMAT) and maintained a price target of $250.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 7:40 pm

ADI

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on Analog Devices (NASDAQ:ADI) and maintained a price target of $250.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 7:39 pm

WEN

Stephens & Co. analyst Jim Salera has reiterated an Equal-Weight rating for Wendy's (NASDAQ:WEN) and maintained a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 7:34 pm

AVGO

Broadcom shares are trading higher following positive analyst actions. Truist Securities maintained a Buy rating and slightly increased its price target, while Cantor Fitzgerald maintained an Overweight rating and significantly raised its price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 7:33 pm

CAT

Deep-pocketed investors are showing significant interest in Caterpillar (NYSE:CAT) options, with a mix of bullish and bearish sentiments. The options activity is unusually high, indicating potential price movements. The stock is currently down 2.38% at $388.78, with a consensus target price of $434.0.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 7:30 pm

NEM

Recent options trading trends in Newmont (NYSE:NEM) show significant activity, with a mix of bullish and bearish sentiments. Large trades include 14 call options and 1 put option, indicating a potential price window of $35.0 to $57.5. Analysts maintain a Buy rating with a target price around $64.0.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 7:30 pm

CELH

Celsius Holdings has seen unusual options activity with a bullish stance from significant investors. 52% of trades were bullish, with a price target range of $15 to $70. The stock is currently trading at $28.69, down 0.45%, and may be approaching oversold territory. Analysts have given it an average target price of $45.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 7:30 pm

RGLS

HC Wainwright & Co. has reiterated its Buy rating for Regulus Therapeutics, maintaining a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 7:30 pm

FCX

Scotiabank analyst Orest Wowkodaw maintains a Sector Perform rating on Freeport-McMoRan (NYSE:FCX) and raises the price target from $52 to $53.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 7:27 pm